CSL Behring L.L.C.

CSL Behring L.L.C., doing business as CSL Behring LLC, is a foreign-owned, for-profit pharmaceutical manufacturer based in King of Prussia, Pennsylvania that supplies plasma-derived and recombinant biotherapeutics to the federal government as a prime contractor on full-and-open (non-set-aside) delivery orders and blanket purchase agreements, with no subcontract footprint in the source data.

CSL Behring operates almost exclusively as a pharmaceutical supplier to the Department of Veterans Affairs Veterans Health Administration across multiple Veterans Integrated Service Networks. The company's federal footprint spans 3,523 prime awards with a combined potential value of $442.6 million, of which $104.5 million has been obligated (24% realization rate). The portfolio is concentrated in specialty pharmaceutical products: 3,323 awards fall under NAICS 327 (Pharmaceutical Preparation Manufacturing), and 3,084 awards carry PSC code for Drugs and Biologicals. Representative work includes delivery orders for HAEGARDA (C1 inhibitor for hereditary angioedema) to Veterans Integrated Service Network 8 valued at $183,903 (July 2026), ANDEMBRY (garadacimab-gxii auto-injector) to VISN 12 valued at $85,484 (September 2026), and emergency procurements of C1 inhibitor to VISN 19 valued at $147,122 (February 2026). All work carries firm fixed-price terms with no set-aside designation.

Customer concentration is acute. Veterans Integrated Service Network 12 alone accounts for $282.4 million combined potential value across 152 awards—64% of the entire portfolio. The top five VISNs (VISN 12, 8, 9, 7, and 22) represent 84% of combined potential value, though they account for only 41% of award count by number. This dollar-to-volume disparity reflects VISN 12's substantial, high-value orders alongside smaller, routine supply calls from other networks. CSL Behring serves 36 distinct federal customer agencies, but the VA dominates overwhelmingly; no other agency appears as a named funding source in the visible award set.

CSL Behring's vehicle position centers on the GSA Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), under which 1,988 task orders carry $150.9 million in combined potential value. The company also holds positions on Federal Supply Schedule V797P5045B (1,135 task orders, $29 million) and an Indefinite Delivery Contract V797P5911XIA (120 task orders, $1.5 million). A single-award Blanket Purchase Agreement with VISN 7 for HAEGARDA 2000/3000 unit vials carries a $113,280 ceiling through June 2023. All awards are delivery orders or BPA calls against these standing vehicles rather than new contract solicitations.

Activity has declined over the past five years. The source records 23 awards in 2022, dropping to 9 in 2023, 2 in 2024, 1 in 2025, and 4 in 2026. This downward trend may reflect saturation in the VA's specialty pharmaceutical procurement or consolidation of smaller orders into fewer, larger delivery orders. No recompete-cliff window is calculated in the source, but the four 2026 awards visible carry immediate or near-term completion dates (July–September 2026), suggesting minimal exposure to multi-year contract recompetes within the next twenty-four months.

CSL Behring operates as a 100% prime contractor with no identified subcontractors. The company manufactures and distributes directly from its King of Prussia facility; all delivery orders specify that location as the place of performance. The company competes in full-and-open procurements without reliance on set-aside categories, positioning it as a large, established pharmaceutical vendor serving federal agencies at commercial market rates negotiated under GSA Schedule vehicles.